MREO

Mereo Biopharma Group Plc ADR

Feb 05 • 04:00PM ET

0.3750

0.0000 0.00 %

Healthcare • Biotechnology • United Kingdom • NASD

Peers: SRPT FATE KURA ADVM RIGL XERS IMUX PRQR CLSD MTEM

Index	-	P/E	-	EPS (ttm)	-0.26	Insider Own	13.57%	Shs Outstand	159.10M	Perf Week	-14.77%
Market Cap	59.66M	Forward P/E	-	EPS next Y	-0.03	Insider Trans	0.00%	Shs Float	137.51M	Perf Month	-1.06%
Enterprise Value	11.36M	PEG	-	EPS next Q	-0.01	Inst Own	68.72%	Short Float	7.14%	Perf Quarter	-78.93%
Income	-41.69M	P/S	116.99	EPS this Y	1.00%	Inst Trans	-3.61%	Short Ratio	0.67	Perf Half Y	-76.42%
Sales	0.51M	P/B	1.28	EPS next Y	42.93%	ROA	-58.57%	Short Interest	9.81M	Perf YTD	-10.01%
Book/sh	0.29	P/C	1.23	EPS next 5Y	12.64%	ROE	-69.98%	52W High	3.21 -88.32%	Perf Year	-88.13%
Cash/sh	0.31	P/FCF	-	EPS past 3/5Y	- 34.82%	ROIC	-89.46%	52W Low	0.20 87.50%	Perf 3Y	-59.90%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	73.60%	Volatility	13.69% 15.88%	Perf 5Y	-86.21%
Dividend TTM	-	EV/Sales	22.28	EPS Y/Y TTM	-5.44%	Oper. Margin	-9340.40%	ATR (14)	0.10	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.71	Sales Y/Y TTM	-	Profit Margin	-8240.08%	RSI (14)	28.46	Recom	1.62
Dividend Gr. 3/5Y	- -	Current Ratio	8.71	EPS Q/Q	55.69%	SMA20	-26.61%	Beta	0.30	Target Price	3.44
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	-68.95%	Rel Volume	0.00	Prev Close	0.38
Employees	36	LT Debt/Eq	0.00	Earnings	Nov 10 AMC	SMA200	-79.88%	Avg Volume	14.65M	Price	0.38
IPO	Apr 24, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-75.44% -98.29%	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-30-25	Downgrade	Jefferies	Buy → Hold	$0.50
Mar-27-25	Initiated	JP Morgan	Overweight	$7
Dec-06-24	Initiated	Jefferies	Buy	$7
Jun-13-24	Initiated	Robert W. Baird	Outperform	$8
Oct-13-23	Resumed	BTIG Research	Buy	$4
Aug-12-22	Initiated	Cantor Fitzgerald	Overweight	$4
May-05-21	Initiated	BTIG Research	Buy	$10
Apr-05-21	Initiated	Needham	Buy	$10

Today 07:30AM	Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights MREO (Business Wire)
Jan-12-26 08:00AM	Mereo BioPharma Provides Corporate Update (GlobeNewswire) +14.75%
Dec-31-25 09:40AM	DigitalBridge downgraded, Commvault initiated: Wall Streets top analyst calls (TipRanks) +12.47%
Dec-30-25 12:39PM	Why Ultragenyx Stock Dropped 42% and What Comes Next (Barrons.com) +29.82%
11:00AM	RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint (Zacks)
09:36AM	Loading…
09:36AM	DigitalBridge downgraded, Commvault initiated: Wall Street's top analyst calls (The Fly)
Dec-29-25 01:05PM	These biotech stocks are getting hammered by shocking brittle-bone treatment study results (MarketWatch) -87.65%
08:31AM	Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta (GlobeNewswire)
Nov-10-25 04:01PM	Mereo BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Highlights (GlobeNewswire) +5.65%
Aug-19-25 08:30AM	ashibio Expands Clinical Pipeline with Vantictumab, a First-In-Class Antibody for Autosomal Dominant Osteopetrosis Type 2 (Business Wire)
Aug-12-25 07:35AM	Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights (GlobeNewswire) +9.21%
Aug-11-25 07:45AM	Mereo BioPharma Group (MREO) Announced Progress in the Phase 3 Orbit Study Testing UX143 (Insider Monkey)
Jul-10-25 10:37AM	Biotech Stock Ultragenyx Is Falling on Unsatisfying Trial Update (Barrons.com) -42.52%
10:34AM	Ultragenyx, Mereo Hammered For Their Surprise Miss In Brittle Bone Disease (Investor's Business Daily)
10:17AM	RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End (Zacks)
07:52AM	Loading…
07:52AM	Kellogg shares soar on buyout talk, and other early market movers (MarketWatch)
Jul-09-25 04:05PM	Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis (GlobeNewswire)
May-13-25 07:30AM	Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights (GlobeNewswire) -7.20%
Apr-16-25 03:00PM	Mereo BioPharma Group plc (MREO): A Bull Case Theory (Insider Monkey) +6.50%
11:23AM	Is Mereo BioPharma Group (NASDAQ:MREO) the Best Biotech Penny Stock to Buy According to Hedge Funds? (Insider Monkey)
Mar-26-25 07:30AM	Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights (GlobeNewswire)
Mar-20-25 12:00PM	MEREO BIOPHARMA (MREO) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-05-25 07:30AM	Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference (GlobeNewswire)
Feb-11-25 11:00AM	Mereo Insurance forays into reinsurance market (Life Insurance International)
Feb-10-25 02:12PM	Ex-AIG Chief Secures $700 Million for Mereo Reinsurance Startup (Bloomberg)
Jan-12-25 11:05AM	Mereo BioPharma Provides Update on Lead Clinical Programs (GlobeNewswire)
Jan-07-25 07:30AM	Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-30-24 02:50PM	Why Mereo BioPharma (MREO) Is One of the Best Biotech Penny Stocks to Invest in Now? (Insider Monkey) -5.63%
Dec-07-24 05:20AM	Mereo BioPharma initiated with a Buy at Jefferies (TipRanks)
Dec-06-24 01:18PM	Mereo BioPharma Stock Climbs Following Jefferies' Buy Rating, Upside Potential of 89% (GuruFocus.com) +8.65%
07:30AM	Loading…
Nov-14-24 07:30AM	Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference (GlobeNewswire) -5.68%
Nov-12-24 07:30AM	Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-16-24 09:06AM	Is Mereo BioPharma Group (MREO) the Hottest Penny Stock to Invest in According to Hedge Funds? (Insider Monkey)
Sep-18-24 08:21AM	Mereo BioPharma Group plc (MREO): A Bull Case Theory (Insider Monkey) +6.84%
Sep-12-24 05:35PM	Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference (GlobeNewswire) -5.79%
Aug-13-24 08:00AM	Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-15-24 11:42PM	Street calls of the week: Upgrade for Shopify; downgrades for AMD, Paramount (Investing.com)
Jun-14-24 07:50AM	Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market (GlobeNewswire) +6.52%
Jun-12-24 07:45AM	Ultragenyx, Mereo drug reduces fractures in bone disorder study (BioPharma Dive) +8.81%
Jun-11-24 05:47PM	Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI) (GlobeNewswire)
May-30-24 07:30AM	Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference (GlobeNewswire) +5.90%
May-15-24 04:01PM	Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +7.09%
Apr-12-24 09:35AM	MEREO BIOPHARMA (MREO) Loses -12.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Apr-03-24 07:30AM	Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-27-24 05:27PM	Mereo BioPharma Group PLC (MREO) Announces Full Year 2023 Financial Results (GuruFocus.com) +10.00%
04:01PM	Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-05-24 07:30AM	Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference (GlobeNewswire)
Feb-16-24 03:57AM	15 Top Performing European Stocks So Far in 2024 (Insider Monkey)
Jan-08-24 07:00AM	Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments (GlobeNewswire)
Dec-19-23 11:21AM	Hedge Funds Say These Penny Stocks Are Poised to Explode (Insider Monkey)
Nov-03-23 11:43AM	Ultragenyx (RARE) Q3 Earnings and Revenues Miss Estimates (Zacks)
Oct-23-23 04:01PM	Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update (GlobeNewswire) -7.89%
Oct-14-23 04:30PM	Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI) (GlobeNewswire)
Oct-09-23 08:00AM	Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI) (GlobeNewswire)
Sep-21-23 07:00AM	Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference (GlobeNewswire) -5.67%
Sep-07-23 07:30AM	Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update (GlobeNewswire)
Aug-10-23 11:04PM	BAKER BROS. ADVISORS LP Acquires Significant Stake in Mereo BioPharma Group PLC (GuruFocus.com) -6.30%
Aug-04-23 08:12AM	Ultragenyx (RARE) Q2 Loss Wider Than Expected, Revenues Beat (Zacks)
Jul-07-23 07:46AM	Ultragenyx (RARE) Doses First Patients in Bone Disease Studies (Zacks) +7.32%
Jul-06-23 08:00AM	Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI) (GlobeNewswire)
May-31-23 07:00AM	Mereo BioPharma to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-23-23 01:43PM	Phase 2 Data from ASTRAEUS Trial of Mereo BioPharmas Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference (GlobeNewswire) -5.47%
May-08-23 12:46PM	Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
May-05-23 04:06PM	Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market (GlobeNewswire)
Apr-21-23 12:00PM	What Makes MEREO BIOPHARMA (MREO) a Strong Momentum Stock: Buy Now? (Zacks) -5.72%
Apr-13-23 08:00AM	Mereo BioPharma to Participate in Fireside Chat at the 22nd Annual Needham Healthcare Conference (GlobeNewswire)
Mar-28-23 04:30PM	Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights (GlobeNewswire)
Mar-21-23 06:30AM	Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease (GlobeNewswire) +16.89%
Feb-08-23 07:00AM	Mereo BioPharma to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-10-23 05:35AM	Positive week for Mereo BioPharma Group plc (NASDAQ:MREO) hedge funds investors who lost 33% over the past year (Simply Wall St.) -7.12%
Nov-15-22 09:35AM	MEREO BIOPHARMA (MREO) Loses 25.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +5.92%
Nov-08-22 07:00AM	Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-02-22 04:01PM	Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency (GlobeNewswire) -6.97% -8.76%
Oct-28-22 07:00AM	Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management (GlobeNewswire)
Oct-24-22 04:30PM	Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022 (GlobeNewswire)
Oct-21-22 07:00AM	Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting (GlobeNewswire)
Oct-18-22 11:58AM	Rubric Capital Management Comments on Mereo BioPharma Updated Operating Plan (Business Wire)
07:00AM	Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value (GlobeNewswire)
Oct-17-22 07:00AM	Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease (GlobeNewswire)
Oct-03-22 05:00PM	Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders (GlobeNewswire) +7.85%
09:00AM	Rubric Capital Management Increases Slate of Proposed Mereo BioPharma Director Nominees to Five (Business Wire)
Sep-28-22 09:21AM	Chinese Billionaire Zhang Lei is Selling These 10 Stocks (Insider Monkey)
Sep-26-22 07:00AM	Mereo BioPharma Offered to Settle Proxy Contest with Rubric Capital Management by Putting Rubric Principal and Second New Director on the Board (GlobeNewswire)
Sep-14-22 09:00AM	Rubric Capital Management Issues Open Letter to Mereo BioPharma Shareholders (Business Wire)
Sep-12-22 08:00AM	Mereo BioPharma Reports Clinical Update and Interim Biomarker Analysis Presented at ESMO 2022 from ACTIVATE Phase 1b/2 Open Label Study of Etigilimab (Anti-TIGIT Antibody MPH-313) plus Nivolumab (Anti-PD-1 Antibody) in Solid Tumors (GlobeNewswire)
Sep-09-22 08:22PM	Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR (GlobeNewswire) +5.94%
Aug-31-22 07:00AM	Mereo BioPharma Sends Letter to Rubric Capital Management (GlobeNewswire)
Aug-22-22 04:00AM	Mereo BioPharma Sends Letter to Rubric Capital Management (GlobeNewswire)
Jul-05-22 04:01PM	Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) -6.52%
Jun-21-22 08:30AM	CEOs of NIO, NEXCF, MREO, and AIMLF Advancing Next Wave of Multi-Billion Dollar Growth Opportunities in Web 3.0, Wearables, Pharma, and Electric Vehicles. (GlobeNewswire) +30.00%
Jun-20-22 10:36AM	Mereo BioPharma (MREO) Up as AstraZeneca Reportedly Eyes Buyout (Zacks)
Jun-17-22 05:30PM	Mereo BioPharm and Theseus Pharmaceuticals See Action From Activist Investors (Barrons.com) +62.50% +30.00%
03:53PM	AstraZeneca weighs bid for Mereo, Carnival Cruises partners with MGM, Devon Energy stock plunges (Yahoo Finance Video)
10:21AM	Why Mereo BioPharma Shares Are Jumping Today (Benzinga)
03:44AM	AstraZeneca weighing bid for Mereo BioPharma: report (MarketWatch)
Jun-02-22 08:00AM	Mereo BioPharma To Present Data Update for the Phase 1b/2 Study (ACTIVATE) of Etigilimab and Nivolumab at 2022 ASCO Annual Meeting; Mereo Also Updates Capital Allocation and Portfolio Prioritization Plan (GlobeNewswire) -5.12%
May-26-22 05:05PM	Mereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) +8.77%
04:30PM	Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency (GlobeNewswire)
May-17-22 08:00AM	Mereo BioPharma Announces Appointment of Dr. Abdul Mullick to Board of Directors (GlobeNewswire)
May-09-22 07:45AM	Mereo BioPharma Shares Jump After Encouraging Alvelestat Data In Lung Disease (Benzinga) -31.30%

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MREO

Mereo Biopharma Group Plc ADR

Upgrade your FINVIZ experience